|
Hi Joe,
Do you happen to know if they will be making available any information on cardiotoxicity?
Here in the UK many oncologists seem unwilling even to give herceptin after treatment (as done in HERA) because of concern over cardiotoxicity, even though this wasn't really much of an issue in HERA. I don't think anybody is getting AC -> (herceptin + taxol), although some seem to be getting the more heart-friendly EC-> (herceptin + taxol). I am concerned that the tremendous reduction in recurrence is being drowned out by the cardiotoxicity concerns.
Any info would be appreciated.
|